MRC / BHF Heart Protection Study "HPS"


Phase N/A Results


Simvastatin significantly reduced the first event rate of stroke vs placebo (444 vs 585, p < 0.0001). There was no significant difference in strokes attributed to hemorrhage (51 vs 53, p=0.8). Simvastatin also reduced the number of patients having transient cerebral ischemic attacks alone (2.0% vs 2.4%, p=0.02) or requiring carotid endarterectomy or angioplasty (0.4% vs 0.8%, p=0.0003). Stroke reduction was not significant in the first year, but was highly significant by the end of the second year (p=0.0004) and continued through the 5 year followup.